Prospective Validation of AKI Prediction
Launched by ADAM C DZIORNY · Jan 27, 2025
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving the way we predict Acute Kidney Injury (AKI) in children who are admitted to the Pediatric Intensive Care Unit (PICU) or Pediatric Cardiac Intensive Care Unit (PCICU). The researchers want to test a special scoring system called the Pediatric Early AKI Risk Score to see how accurately it can identify patients at risk for AKI within the first 72 hours of being in the ICU. They will do this by collecting data in a way that the clinical team cannot see, to ensure unbiased results. The goal is to have the scoring system identify AKI correctly more than 70% of the time.
To be eligible for this study, patients must be between 30 days and 17 years old and must be admitted to one of the specialized intensive care units mentioned. However, those who are discharged less than 12 hours after admission or who already have AKI when they arrive will not be included. Participants in the trial can expect that their information will be used to help improve future care for children at risk of kidney injury. This study is currently not recruiting participants, but it aims to gather important insights for better treatment options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients admitted to the Pediatric Intensive Care Unit or Pediatric Cardiac Intensive Care Unit
- • Age \> 30 days and \< 18 years
- Exclusion Criteria:
- • Discharged less than 12 hours after admission
- • AKI at 12 hours of admission by KDIGO Serum Criteria
About Adam C Dziorny
Adam C. Dziorny is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic approaches, Mr. Dziorny oversees the design, implementation, and management of clinical studies, ensuring adherence to regulatory standards and ethical guidelines. His expertise in trial methodology, coupled with a strong emphasis on collaboration with research institutions and healthcare professionals, fosters a robust environment for scientific discovery. Through meticulous planning and execution, Adam C. Dziorny aims to contribute to the development of novel treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported